Elevated serum creatinine over the first week of life and mortality risk in extremely preterm neonates: a secondary analysis of the Preterm Erythropoietin Neuroprotection Trial (PENUT).

Pediatr NephrolApr 21, 2026 (epub)
Clinical ResearchPediatricsOpen access

Melissa S Zhou, Russell Griffin, David J Askenazi et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of the Preterm Erythropoietin Neuroprotection Trial evaluated the association between elevated serum creatinine (SCr) levels and mortality risk in extremely preterm neonates (<28 weeks gestational age). Among 918 neonates, those with 95th-AKI had a significantly higher in-hospital mortality rate of 18% compared to 9% in controls, with an adjusted hazard ratio of 2.16 for 95th-AKI.

Key findings

  • 12% of neonates had KDIGO-AKI, while 8% had 95th-AKI.
  • In-hospital mortality was 18% for both 95th-AKI and KDIGO-AKI groups compared to 9% for controls.
  • 95th-AKI was associated with an adjusted HR of 2.16 for increased in-hospital mortality.

Why it matters

Identifying neonates at risk for mortality through specific serum creatinine thresholds can enhance early intervention strategies, potentially improving outcomes in extremely preterm infants.

Source

PubMed · PMID 42012687Free full text on PubMed Central

Published in Pediatr Nephrol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.